<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948919</url>
  </required_header>
  <id_info>
    <org_study_id>GI-2019-27285</org_study_id>
    <nct_id>NCT03948919</nct_id>
  </id_info>
  <brief_title>Low Sulfur Fecal Transplant for Ulcerative Colitis</brief_title>
  <official_title>Low Sulfur Fecal Transplant for Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the engraftment of donor microbiota's sulfate&#xD;
      reducing bacteria (SRB) in subjects with active ulcerative colitis (UC) following sequential&#xD;
      fecal microbiota transplant (FMT). Specifically this study will evaluate if low SRB donor&#xD;
      microbiota translates to lower SRB microbiota in the UC recipient. It is widely unknown if&#xD;
      the microbiota in UC is dysfunctional and therefore perpetuates inflammation, or if the&#xD;
      ongoing inflammation shapes the microbiota. Patients with UC have a higher relative abundance&#xD;
      of SRB compared to healthy controls. It is the aim of this study to determine if the&#xD;
      microbiota in UC can be altered to favor a low SRB fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory bowel disease (IBD) is a chronic, relapsing remitting inflammatory disease of&#xD;
      the intestine. The two main forms of IBD are Crohn's disease (CD) and Ulcerative Colitis&#xD;
      (UC). There is no cure for IBD and the etiology is unknown, however IBD is thought to arise&#xD;
      as an aberrant immune response to the intestinal microbiota. The intestinal microbiota&#xD;
      closely correlates with inflammation in IBD. Currently, the treatment of IBD is based on&#xD;
      suppressing the aberrant immune response in the intestine. This often takes the form of&#xD;
      systemic immunosuppression, which in turn carries a multitude of risks including infection&#xD;
      and malignancy. Thus there is an urgent need for safe, effective therapies that ultimately&#xD;
      have the potential to cure IBD.&#xD;
&#xD;
      Fecal microbiota transplantation (FMT) is the process of transferring fecal microbiota from&#xD;
      one individual to another. FMT has revolutionized the treatment of multiple recurrent&#xD;
      Clostridium difficile infection with a cure rate around 90%. Given the success of FMT in C.&#xD;
      difficile colitis, attention turned to other forms of colitis, in particular IBD. Early pilot&#xD;
      studies demonstrated a mixed result for the use of FMT in IBD. One of the key issues&#xD;
      surrounding the use of FMT in IBD is the challenge of engrafting a new microbiota.&#xD;
      Additionally IBD flares following FMT for C. difficile infection have been reported, although&#xD;
      it is difficult to account for the confounding of the underlying C. difficile infection. This&#xD;
      study will examine how FMT donor selection can impact the engraftment of the microbiota into&#xD;
      patients with UC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment of low sulfate reducing microbiota</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in quantitative PCR of sulfate reducing genes from baseline to week 12 between FMT arm and placebo arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change of sulfate reducing microbiota</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in quantitative PCR of sulfate reducing genes at week 1, 2, 3 and 4 between FMT arm and placebo arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of FMT versus placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in partial Mayo score from baseline to week 8 between FMT and placebo arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of low sulfate reducing microbiota</measure>
    <time_frame>12 weeks</time_frame>
    <description>Partial mayo score at week 12 between those with low sulfate reducing microbiota or not low sulfate reducing microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of serious adverse events between FMT arm and placebo arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>FMT Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fecal microbiota - 1.0-3.0 x 10^11 CFU / day (2 capsules per day for 8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product. Two capsules taken daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal microbiota</intervention_name>
    <description>Lyophilized encapsulated fecal microbiota given daily for 8 weeks.</description>
    <arm_group_label>FMT Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to provide consent&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Diagnosis of ulcerative colitis based on typical clinical-histopathic diagnosis&#xD;
&#xD;
          -  Diagnosis of ulcerative colitis &gt; 3 months&#xD;
&#xD;
          -  Active disease on endoscopy (endoscopic Mayo subscore ≥ 1)&#xD;
&#xD;
          -  Evidence of inflammation extending beyond a minimum of 20cm&#xD;
&#xD;
          -  Any ongoing ulcerative colitis therapy must be at stable doses for 4 weeks prior to&#xD;
             study and remain stable over the course of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extensive bowel resection&#xD;
&#xD;
          -  Presence of ileostomy or colostomy&#xD;
&#xD;
          -  Suspicion of ischemic colitis, radiation colitis or microscopic colitis&#xD;
&#xD;
          -  Diagnosis of Crohn's disease&#xD;
&#xD;
          -  Diagnosis of per-anal fistula or abscess&#xD;
&#xD;
          -  Adenomatous polyps that have not been removed&#xD;
&#xD;
          -  Use of pre or probiotics within 30 days of randomization&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe food allergies&#xD;
&#xD;
          -  End stage liver disease or cirrhosis&#xD;
&#xD;
          -  An absolute neutrophil count &lt; 500 cell/µL&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daria Kozysa, B.S.</last_name>
    <phone>612-626-1776</phone>
    <email>kozys002@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Kabage, M.S.</last_name>
    <phone>612-624-2956</phone>
    <email>kabage@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byron Vaughn</last_name>
      <phone>612-626-1776</phone>
      <email>kozys002@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

